一品紅(300723.SZ):與晟德大藥廠簽署終止合作協議、品晟醫藥將成為公司間接出資的全資子公司
格隆匯5月12日丨一品紅(300723.SZ)公佈,公司全資子公司廣州一品紅製藥有限公司(“一品紅製藥”)於近日與合作方晟德大藥廠股份有限公司(“晟德大藥廠”;台灣上櫃公司,股票代碼:4123)及其子公司Centerlab Investment Holding Limited (“Centerlab Investment”)簽署了《廣東品晟醫藥科技有限公司(“品晟醫藥”)股權轉讓合同》、《增資協議書之解除協議》和《合作開發協議之解除協議》,自上述合同及協議簽署之日起,各合作方就項目合作所簽署的各類合同、協議等法律文件全部解除或終止,各方將按約定將品晟醫藥的部分股權轉讓給一品紅製藥。此次交易完成後,品晟醫藥將成為公司間接出資的全資子公司。
未來,公司將積極利用各方面資源,圍繞“特色兒童藥、創新慢病藥、生物基因疫苗”的發展戰略,積極開展創新藥和高端藥品研發,不斷豐富公司產品管線。通過內生式增長和外延式發展推動公司各項業務快速穩定發展,持續提升盈利能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.